Longer-acting growth hormone reduces frequency of injections. It will be available in August.
Pfizer and OPKO Health’s new pediatric growth hormone treatment, Ngenla (somatrogon-ghla), approved by the FDA on June 28, has a monthly wholesale acquisition cost (WAC) of $8,300, a Pfizer spokesperson told Formulary Watch.
Ngenia, which will be available in August, is a once-weekly, human growth hormone analog for pediatric patients 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone. The price is generally in line with other once weekly growth hormone treatments, the spokesperson said.
“The price of Ngenla reflects Pfizer’s long-standing commitment of bringing exceptional value to our payer customers in the rare disease space. We are committed to continuing to work with our payer customers on partnerships to help ensure access to Ngenla for patients who need it,” the spokesperson said.
Pfizer is committed to working in collaboration with a variety of stakeholders, including healthcare providers, advocates, policymakers, and payers, to help ensure access for patients, the spokesperson said. Additionally, the company is committed to “helping patients access the treatments they need and there will be copay savings and patient assistance programs to help achieve this. Through the Pfizer Bridge Program, eligible patients will be able to get support with access to Ngenla.”
Ngenla offers a new treatment option for children living with growth hormone deficiency. “Currently the standard of care is a once-daily injection administered subcutaneously. It is estimated that up to two-thirds of children with GHD may miss more than one daily dose per week. The inclusion of Ngenla in the treatment paradigm enables children to reduce treatment frequency from once-daily to once-weekly injections, thus minimizing the treatment burden for children that can lead to treatment nonadherence,” the spokesperson added.
“The approval of Ngenla will be significant for children with growth hormone deficiency in the U.S. It holds potential to reduce the treatment burden that can come with daily growth hormone injections,” Joel Steelman, M.D., pediatric endocrinologist at Cook Children’s Health Care System, said in the Pfizer news release. “As a new, longer-acting option that has the ability to reduce treatment frequency from daily to weekly, Ngenla could become an important treatment option that can improve adherence for children being treated for growth hormone deficiency.”
FDA’s approval is supported by results from a multi-center, randomized, open-label, active-controlled phase 3 study which evaluated the safety and efficacy of Ngenla when administered once-weekly compared with once-daily somatropin (Serostim). The study met its primary endpoint of Ngenla non-inferiority compared with somatropin, as measured by annual height velocity at 12 months. Ngenla was generally well-tolerated in the study and had a safety profile comparable to somatropin, Pfizer said.
Ngenla is also approved to treat pediatric growth hormone deficiency in more than 40 markets including Canada, Australia, Japan, and EU member states.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen